High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of ...

SAN DIEGO and SUZHOU, China - Adagene Inc. (NASDAQ: ADAG), a biotechnology firm with a market capitalization of $85 million ...

The company announced interim data showing strong systemic responses in its safety and efficacy study combining Alpha DaRT treatment with ...

RenovoRx, Inc. ("RenovoRx" or the "Company") , a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today ...

This piece is part of a series that dives deeper into the most prevalent themes of this year’s iteration of our flagship research piece, Charting Disruption. Click to read.

WCG, a global leader in providing solutions that measurably improve and accelerate clinical research, today announced the launch of ClinSpheretm Total Enrollment. This software-as-a-service technology ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...

Despite progress in healthcare services for individuals living with sickle cell disease (SCD) in Africa, substantial gaps ...

Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec” or the "Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence ...

I recently was invited to give a presentation about genomic alterations in AML at the 2024 ASTCT Clinical Education Conference for advanced practice providers, nurses and fellows.I was pleased to have ...

(IN BRIEF) Roche has reported positive results from the second year of the EMBARK Phase III trial of Elevidys (delandistrogene moxeparvovec), the first approved gene therapy for Duchenne muscular ...

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.